中新网广州1月18日电 (记者 王坚)据广州市南沙区政府18日消息，该区近期出台并实施了一系列面向高 校毕业生的支持政策，涵盖从面试、实习到就业、安居乃至创业的全周期。 广州南沙(资料图)。南沙区政府 供图 据了解，这些政策旨在降低青年人才来南沙发展的初始成本，构筑人才服务保障体系。 从实验室走向创业场，类似智科自动化这样的案例在南沙逐渐增多。南沙在人工智能、生物医药等重点 产业领域扶持了一批创新平台，精准匹配企业发展需求，也为高端人才提供了参与产业创新的机会。 (完) 近年来，南沙针对企业和人才的实际需求，在创新创业、子女教育、生活配套等关键领域持续推出支持 措施，着力构建"后勤"支撑体系，让人才能够专注于事业发展。 系列政策在吸引人才的同时，也致力于搭建创新创业的舞台。"我们完成千万级天使轮融资，拓展研发 团队、购置设备，在基地搭建了近1000平方米的生产车间，发展走上快车道。"智科自动化负责人陈远 志在回顾企业一年来的发展时说道。 该公司由港科大(广州)智能制造学域主任汤凯教授带领3名博士生联合创立，因在港科大百万奖金国际 创业大赛中获奖而受到关注。2025年初入驻位于南沙的港科大(广州)科创成果转移转 ...

Core Viewpoint - The "Nannong Xiaoi" mini cucumber, characterized by its straight shape, lack of spines, and tender, crispy sweetness, was showcased at the third Social Cooperation Innovation Development Conference held by Nanjing Agricultural University on January 17, as one of the "Top Ten Agricultural Science and Technology Application Achievements" for 2025 [1][3]. Group 1: Agricultural Innovations - The top ten achievements include new varieties and technologies that address production pain points, injecting new momentum into high-quality agricultural development [3]. - "Nannong Xiaoi" is designed to optimize planting time and improve production efficiency for farmers, utilizing existing strawberry cultivation facilities for vertical planting during the idle period from May to August [3]. - The yield of "Nannong Xiaoi" can exceed 3,000 kilograms per acre, with an average income of over 12,000 yuan per acre [3]. Group 2: Modern Agricultural Development Center - The first concept validation center in Jiangsu's modern agricultural sector was inaugurated, focusing on organized transformation and optimizing the integration of talent, achievements, capital, and market elements [5]. - The center aims to enhance the discovery of technological value and facilitate the transfer and transformation of scientific achievements, concentrating on areas such as biological breeding, smart agriculture, biomedicine, and future foods [5]. - Nanjing Agricultural University is collaborating with the Nanjing National Agricultural Innovation Center to select promising research outcomes for validation, with several projects already listed for initial concept validation [5]. Group 3: Strategic Direction - The university plans to align its research with national strategies, addressing urgent industry needs and transitioning research topics from "disciplinary logic" to "industry logic" to ensure that innovative outcomes are practical and applicable [5]. - There is an ongoing effort to establish a university science park to cultivate new niches and dynamics, facilitating the transition of innovative results from academic papers to practical applications in production [5].

Core Insights - The 2025 VC/PE market report indicates a significant increase in both the number and amount of funds raised, with a year-on-year growth of approximately 30% [4][5]. Group 1: VC/PE Market Fundraising Analysis - In 2025, a total of 6,127 new funds were established in China's VC/PE market, representing a 27% increase from the previous year, with a total fundraising scale of 30,860 billion yuan, up 26% year-on-year [8]. - The number of institutions participating in fund establishment rose to 3,180, a 13.01% increase from last year, with 62% of institutions setting up one fund, and 19.4% establishing three or more funds, up from 15% the previous year [8]. - Zhejiang province led with 1,367 new funds, followed by Jiangsu and Guangdong with 967 and 644 funds respectively, while some provinces like Anhui and Hubei saw a slight decline [12]. Group 2: Investment Analysis - In 2025, the number of investment cases reached 11,015, a 30.6% increase, with total investment amounting to 13,396.8 billion yuan, up 23.43% year-on-year [32]. - The average investment amount was 1.22 million yuan, showing a slight decrease compared to the previous year [32]. - The top 250 investment institutions accounted for 7.7% of the total market, with a 16.69% increase in the number of participating institutions compared to the previous year [36]. Group 3: Exit Market Analysis - In 2025, 294 Chinese companies achieved IPOs, with 170 of these backed by VC/PE institutions, resulting in a slight decrease in penetration rate to 57.8% [59]. - The exit return rate dropped to 289%, with the proportion of overseas IPOs increasing to 61% [59].

Core Viewpoint - Maiwei Biotech's stock has shown volatility with a recent increase of 2.03%, but has experienced a decline of 6.71% over the past five trading days, indicating mixed market sentiment [1] Group 1: Stock Performance - As of January 16, Maiwei Biotech's stock price is 42.70 CNY per share, with a market capitalization of 17.063 billion CNY [1] - The stock has increased by 11.00% year-to-date, but has seen a decline of 4.37% over the past 60 days [1] - Trading volume on January 16 reached 2.31 million CNY, with a turnover rate of 2.71% [1] Group 2: Financial Performance - For the period from January to September 2025, Maiwei Biotech reported revenue of 566 million CNY, reflecting a year-on-year growth of 301.03% [2] - The company recorded a net profit attributable to shareholders of -598 million CNY, which is a year-on-year increase of 13.89% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has increased by 9.15% to 19,600, while the average number of circulating shares per person has decreased by 8.38% to 10,425 shares [2] - Notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the fourth largest shareholder with 3.1746 million shares, and South China CSI 1000 ETF, which is a new entrant among the top ten shareholders [2]

Group 1: Domestic Market and Consumption - The core message emphasizes the importance of building a strong domestic market and expanding high-level openness in the context of the "14th Five-Year Plan" [1] - In the first 11 months of 2025, China's retail sales of consumer goods are expected to grow by 4.0% year-on-year, with the total expected to exceed 50 trillion yuan for the first time [1] - China aims to focus on sectors such as transportation, home services, performances, and sports events to cultivate new growth points in service consumption [1] - Measures will be taken to enhance circulation facilities and enrich consumption scenarios to stimulate potential in lower-tier markets [1] - The government will support the consumption of green and smart products, including subsidies for new smart devices, and promote a balanced development of online and offline retail [1] Group 2: Foreign Trade and Economic Cooperation - China's foreign trade is expected to show resilience, with total goods imports and exports projected to exceed 45 trillion yuan for the first time, maintaining its position as the world's largest trading nation for nine consecutive years [2] - The country plans to advance goods trade, service trade, and digital trade in a coordinated manner, while promoting balanced trade development [2] - The government will improve the management system for the negative list of cross-border service trade and gradually open up market access in service sectors [2] - There will be a focus on expanding exports of productive services, leveraging advantages in artificial intelligence, digital economy, and biomedicine to cultivate new growth points in foreign trade [2] - China will actively expand autonomous openness in various service sectors and participate constructively in global economic governance [2]

Core Viewpoint - The Ministry of Commerce emphasizes the need to address challenges and uncertainties in foreign trade, focusing on the construction of a trade powerhouse through three pillars: goods trade, service trade, and digital trade [1]. Group 1: Trade Promotion Strategies - The Ministry plans to enhance major trade exhibitions like the Canton Fair to attract more overseas buyers and increase support for companies participating in international exhibitions [3]. - There will be an optimization of public services, including the publication of country-specific trade guides and foreign trade promotion information [3]. - The Ministry aims to guide the healthy and regulated development of new foreign trade models such as cross-border e-commerce [3]. Group 2: Trade Agreements and Market Expansion - China has established 23 free trade agreements with 30 countries and regions, and the Ministry will support companies in utilizing these agreements to expand trade [3]. - The "Export China" initiative, launched during the last China International Import Expo, will continue to enhance brand influence and organize various matching activities to boost imports [3]. Group 3: Import Trade Facilitation - The Ministry will leverage trade promotion platforms like the China International Import Expo to improve the convenience of import trade and optimize the sources and structure of imported goods [3]. - There is a commitment to meet the needs of industrial development and improve the quality of life for citizens through better import strategies [3]. Group 4: Service Trade Development - The Ministry plans to refine the negative list management system for cross-border service trade and gradually relax market access in service sectors [3]. - Policies will be developed based on the "one industry, one policy" principle to promote high-value measures, accelerate the export of productive services, and enhance the international service capabilities of professional service institutions [3]. - The focus will be on leveraging innovations in artificial intelligence, digital economy, and biomedicine to expand exports in emerging services such as R&D, design, consulting, testing, and maintenance [3].

Core Viewpoint - Junshi Biosciences has experienced fluctuations in stock price and trading volume, with a recent decline in share price despite a year-to-date increase. The company is involved in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with a significant portion of its revenue coming from drug sales [1][2]. Group 1: Stock Performance - On January 16, Junshi Biosciences' stock fell by 2.00%, trading at 36.72 CNY per share, with a total market capitalization of 37.7 billion CNY [1]. - The stock has increased by 7.49% year-to-date but has seen a decline of 6.33% over the last five trading days [1]. - The trading volume was 1.76 billion CNY, with a turnover rate of 0.62% [1]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06% [2]. - The company recorded a net profit attributable to shareholders of -596 million CNY, which is a 35.72% increase compared to the previous period [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased to 35,900, a rise of 15.17% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 12.96% to 21,361 shares [2]. Group 4: Company Overview - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, is based in Shanghai and focuses on the development and commercialization of monoclonal antibody drugs and other therapeutic proteins [1]. - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [1].

Core Viewpoint - The stock of Zhifei Biological experienced a decline, with a current price of 19.03 yuan per share and a market capitalization of 45.554 billion yuan, reflecting a challenging financial performance in recent periods [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a significant year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion yuan, marking a year-on-year decline of 156.10% [2]. - The company has cumulatively distributed dividends of 7.318 billion yuan since its A-share listing, with 3.194 billion yuan distributed over the past three years [3]. Shareholder and Market Activity - As of December 19, 2025, the number of shareholders for Zhifei Biological was 124,500, a decrease of 2.69% from the previous period, while the average circulating shares per person increased by 2.76% to 11,358 shares [2]. - The stock experienced a net outflow of main funds amounting to 25.6679 million yuan, with significant selling pressure observed in large orders [1]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is primarily engaged in the research, production, and sales of vaccines and biological products. Its revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. - The company operates within the pharmaceutical and biological industry, specifically in the vaccine sector, and is associated with concepts such as hepatitis treatment, vaccines, anti-influenza, biomedicine, and innovative drugs [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders included Hong Kong Central Clearing Limited, holding 33.5608 million shares, and several ETFs, all of which saw a reduction in their holdings compared to the previous period [3].

院士（专家）创新工作站是推动产学研协同创新、促进科技成果转化的重要平台。由来自高校科 研院所等机构的院士、专家团队与企事业等单位或机构建立工作站，旨在实现优势互补、合作共 赢。 记者梳理发现，2025年新增加的20家工作站紧密围绕成都市"9+9+10"现代化产业体系布局，建站 单位均为国家高新技术企业，覆盖人工智能、新材料、生物医药、低空经济等重点产业领域。 本报讯（四川日报全媒体记者 熊晓雨）近日，记者从成都市科协获悉，2025年成都市新认定院士 （专家）创新工作站20家。至此，全市累计建站总数达300家。近三年，通过这一平台柔性引进两 院院士及其团队等高层次专家共计171名。 一个显著特点是专家来源不断拓展。新建站签约的院士（专家）中，除在蓉单位外，不乏来自中 国科学院地理科学与资源研究所、北京应用物理与计算数学研究所、华中科技大学等知名高校院 所的领军学者，显示出成都创新资源吸引力持续增强。 据统计，目前成都全市共计241家工作站续存运行，近三年累计实施产学研合作项目400余项，获 得授权专利近1500项，牵头或参与制定标准200余项，取得经鉴定的科技成果150项，有效提升了 企业的自主创新能力。 "下 ...

Core Insights - The consumer confidence index in Shanghai shows a comprehensive recovery among the youth demographic aged 20 to 39, indicating positive economic sentiment [1][2] Group 1: Consumer Confidence Index - The overall consumer confidence index for Shanghai is reported at 90.63 points, with the consumer evaluation index at 90.17 points and the consumer expectation index at 91.32 points, all remaining stable compared to the previous quarter [1] - The youth group has a confidence index of 94.0 points, which is significantly higher than the middle-aged group, while the elderly group stands at 95.4 points, showing a minor difference that lacks statistical significance [1] Group 2: Factors Influencing Youth Confidence - The recovery in youth confidence is attributed to the development of emerging industries in Shanghai, such as artificial intelligence, biomedicine, and integrated circuits, which create numerous job opportunities [2] - Government policies, including entrepreneurship subsidies and vocational training support, have alleviated employment pressures for the youth, enhancing income expectations and boosting consumer confidence [2] Group 3: Employment and Income Dynamics - Youth income evaluation and expectation indices have increased significantly by 7.3 points and 8.2 points, respectively, while employment evaluation and expectation indices have risen by 8.7 points and 4.4 points, indicating a positive trend [2] - The favorable employment situation for youth is a result of Shanghai's efforts to stabilize and promote employment through an optimized business environment and the rapid development of sectors like internet and technology services [2] Group 4: Future Implications - The rise in consumer confidence among the youth is expected to inject vitality into Shanghai's consumer market, highlighting the significant potential for consumption within this demographic [2] - It is recommended that Shanghai continues to support emerging industries, create more job opportunities tailored for youth, and enhance policies for employment and entrepreneurship to further unlock consumption potential [2]